CoChat

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

Background Activation of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40) by fatty acids stimulated glucose-dependent β-cell insulin secretion in preclinical models. We aimed to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.Methods We undertook a phase 2, randomised, double-blind, and placebo-controlled and active-comparator-controlled trial in outpatients with type 2 diabetes who had not responded to diet or metformin treatment. Patients were randomly assigned equally to receive placebo, TAK-875 (6·25, 25, 50, 100, or 200 mg), or glimepiride (4 mg) once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary outcome was change in haemoglobin A(1c) (HbA(1c)) from baseline. Analysis included all patients randomly assigned to treatment groups who received at least one dose of double-blind study drug. The trial is registered at ClinicalTrials.gov, NCT01007097.Findings 426 patients were randomly assigned to TAK-875 (n=303), placebo (n=61), and glimepiride (n=62). At week 12, significant least-squares mean reductions in HbA(1c) from baseline occurred in all TAK-875 (ranging from -1·12% [SE 0·113] with 50 mg to -0·65% [0·114] with 6·25 mg) and glimepiride (-1·05% [SE 0·111]) groups versus placebo (-0·13% [SE 0·115]; p value range 0·001 to <0·0001). Treatment-emergent hypoglycaemic events were similar in the TAK-875 and placebo groups (2% [n=7, all TAK-875 groups] vs 3% [n=2]); significantly higher rates were reported in the glimepiride group (19% [n=12]; p value range 0·010-0·002 vs all TAK-875 groups). Incidence of treatment-emergent adverse events was similar in the TAK-875 overall (49%; n=147, all TAK-875 groups) and placebo groups (48%, n=29) and was lower than in the glimepiride group (61%, n=38).Interpretation TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes.Funding Takeda Global Research and Development.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)61879-5

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 3

  1. Tsujihata, 2010, TAK-875, a novel, orally available GPR40 agonist, augments, glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats, Diabetes, 59, A165
  2. Takeuchi, 2010, A selective GPR40 agonist, TAK-875, stimulates glucose-dependent insulin secretion without beta cell toxicity and decreases glycosylated hemoglobin levels in diabetic rats, Diabetologia, 53, S353
  3. Leifke, 2011, Safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-875, a novel GPR40 agonist, following once-daily oral administration for 2 weeks in type 2 diabetic patients [abstract 414-PP], Diabetes, 60, A114

Cited by

See all 244

Metadata

Authors
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E.
Affiliations
  • University of Michigan (US)
  • Takeda (United States) (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-04
Volume
379
Issue
9824
Pages
1403-1411
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2163448046
Cited by
244
References
26
Citations by year
2026: 3 · 2025: 6 · 2024: 9 · 2023: 2 · 2022: 8 · 2021: 14 · 2020: 13 · 2019: 13 · 2018: 18 · 2017: 14 · 2016: 28 · 2015: 19 · 2014: 37 · 2013: 36 · 2012: 24
FWCI
30.39
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
TAK-875, free fatty acid receptor 1, GPR40, type 2 diabetes, glimepiride, glycemic control, HbA1c, hypoglycemia, insulin secretion, GLP-1 receptor agonists, adverse events
MeSH terms
Adult, Aged, Aged, 80 and over, Benzofurans, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfones, Sulfonylurea Compounds, Treatment Outcome, Risk Assessment, Maximum Tolerated Dose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(11)61879-5
The paper
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(11)61879-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.